Analgesics
Antiandrogens
Antihistamines
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Monoclonals
Mpro inhibitors
Naso/orophar..
Nigella Sativa
Nitazoxanide
PPIs
Quercetin
RdRp inhibitors
Thermotherapy
Vitamins
More

Other
Feedback
Home
 
next
study
previous
study
c19early.org COVID-19 treatment researchBrexanoloneBrexanolone (more..)
Metformin Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta PPIs Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta
Ivermectin Meta Thermotherapy Meta
Melatonin Meta

All Studies   All Outcomes       

A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19

Brown et al., NCT04537806, NCT04537806
Jul 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality, day 40 -14% Improvement Relative Risk Mortality, day 28 -33% Respiratory failure or death 0% Brexanolone  Brown et al.  VENTILATED PATIENTS  DB RCT Is late treatment with brexanolone beneficial for COVID-19? Double-blind RCT 29 patients in the USA No significant difference in outcomes seen c19early.org Brown et al., NCT04537806, July 2022 Favorsbrexanolone Favorscontrol 0 0.5 1 1.5 2+
RCT 28 ventilated patients, showing no significant difference with brexanolone treatment.
Standard of Care (SOC): SOC for COVID-19 in the study country, the USA, is very poor with very low average efficacy for approved treatments1. Only expensive, high-profit treatments were approved. Low-cost treatments were excluded, reducing the probability of treatment—especially early—due to access and cost barriers, and eliminating complementary and synergistic benefits seen with many low-cost treatments. This may explain in part the very high mortality seen in this study. Results may differ in countries with improved SOC.
risk of death, 14.3% higher, RR 1.14, p = 1.00, treatment 8 of 14 (57.1%), control 7 of 14 (50.0%), day 40.
risk of death, 33.3% higher, RR 1.33, p = 0.71, treatment 8 of 14 (57.1%), control 6 of 14 (42.9%), day 28.
respiratory failure or death, no change, RR 1.00, p = 1.00, treatment 10 of 14 (71.4%), control 10 of 14 (71.4%), day 28.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Brown et al., 27 Jul 2022, Double Blind Randomized Controlled Trial, placebo-controlled, USA, preprint, 1 author, trial NCT04537806 (history). Contact: info@sagerx.com.
This PaperBrexanoloneAll
Late treatment
is less effective
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit